Study identification

PURI

https://redirect.ema.europa.eu/resource/50712

EU PAS number

EUPAS49271

Study ID

50712

Official title and acronym

Real-world Evidence of the Use of a Carfilzomib Triplet Including an Anti-CD38 Antibody in Patients With Multiple Myeloma who Have Received at Least one Prior Therapy (20200445)

DARWIN EU® study

No

Study countries

Finland
France
Germany
Greece
Italy
Portugal
Spain

Study status

Cancelled
Research institutions and networks

Institutions

Amgen
United States
First published:
21/02/2024
Institution

Contact details

Global Development Leader Amgen Inc.

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:

Study start date

Planned:

Data analysis start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Amgen
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable